Biovie Inc Stock In The News

BIVI Stock  USD 2.82  0.18  6.00%   
Our overall analysis of Biovie's news coverage and content from conventional and social sources shows investors' bearish mood towards Biovie Inc. The specific impact of Biovie news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Biovie's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Biovie headlines in addition to utilizing other, more conventional financial analysis modules. Check out Biovie Backtesting and Biovie Hype Analysis.

Biovie Today Top News and Investor Outlook

Yahoo News
18 Best 52-Week Low Stocks To Buy Now
https://finance.yahoo.com/news/18-best-52-week-low-102910064.html
 Bullish
Macroaxis News: globenewswire.com
BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
https://www.globenewswire.com/news-release/2023/11/30/2788910/32716/en/BioVie-BIVI-Plunges-After-Alzheimer-s-Drug-Fails-Phase-3-Due-to-Protocol-Deviations-at-Trial-Sites-Hagens-Berman.html
 Neutral
Macroaxis News: globenewswire.com
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
https://www.globenewswire.com/news-release/2023/11/29/2787674/0/en/BioVie-Announces-Efficacy-Data-from-Phase-3-Trial-of-NE3107-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html
 Neutral
Macroaxis News: globenewswire.com
BioVie Presents Positive Clinical Safety...
https://www.globenewswire.com/news-release/2023/11/13/2779020/0/en/BioVie-Presents-Positive-Clinical-Safety-Data-from-Phase-2b-Trial-of-BIV201-in-Refractory-Ascites-at-the-American-Association-for-the-Study-of-Liver-Disease-AASLD-The-Liver-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
BioVie to Participate in the Truist Securities BioPharma Symposium
https://www.globenewswire.com/news-release/2023/11/02/2772222/0/en/BioVie-to-Participate-in-the-Truist-Securities-BioPharma-Symposium.html
 Bullish
Macroaxis News: globenewswire.com
BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET
https://www.globenewswire.com/news-release/2023/10/30/2769132/0/en/BioVie-to-Host-Conference-Call-and-Webcast-Wednesday-November-1-2023-at-8-00-AM-ET.html
 Neutral
Macroaxis News: globenewswire.com
BioVie Announces Late-Breaking Abstract ...
https://www.globenewswire.com/news-release/2023/10/26/2767473/0/en/BioVie-Announces-Late-Breaking-Abstract-Presenting-Clinical-Safety-Data-from-the-Company-s-Ascites-Phase-2-Trial-Accepted-for-Presentation-at-AASLD-The-Liver-Meeting-2023.html
 Neutral
Macroaxis News: globenewswire.com
Blinded Data Presented at CTAD Suggest t...
https://www.globenewswire.com/news-release/2023/10/25/2766809/0/en/Blinded-Data-Presented-at-CTAD-Suggest-that-NE3107-is-Biologically-Active-and-May-Have-Impact-on-Cognitive-Biomarker-and-Imaging-Endpoints-Among-Mild-to-Moderate-Alzheimer-s-Diseas.html
 Neutral
Macroaxis News: globenewswire.com
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
https://www.globenewswire.com/news-release/2023/10/19/2763073/0/en/BioVie-to-Present-Blinded-Data-on-NE3107-in-the-Treatment-of-Mild-to-Moderate-Alzheimer-s-Disease-at-CTAD.html
 Bullish
Macroaxis News: globenewswire.com
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
https://www.globenewswire.com/news-release/2023/09/26/2749457/0/en/BioVie-Announces-Completion-of-Last-Patient-Treatment-Visit-in-Phase-3-Trial-of-NE3107-in-Mild-to-Moderate-Alzheimer-s-Disease.html
 Neutral

Biovie Inc Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Biovie and other traded companies coverage with news coverage. We help investors stay connected with Biovie headlines for the 27th of November to make an informed investment decision based on correlating the impacts of news items on Biovie Stock performance. Please note that trading solely based on the Biovie Inc hype is not for everyone as timely availability and quick action are needed to avoid losses.
Biovie's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Biovie Inc investors visualize upcoming and past events in order to time the market based on Biovie Inc noise-free hype analysis.
Biovie stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Biovie earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Biovie that are available to investors today. That information is available publicly through Biovie media outlets and privately through word of mouth or via Biovie internal channels. However, regardless of the origin, that massive amount of Biovie data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biovie news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biovie relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biovie's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biovie alpha.

Biovie Largest EPS Surprises

Earnings surprises can significantly impact Biovie's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-09-27
2022-06-30-0.37-0.330.0410 
2023-05-12
2023-03-31-0.35-0.43-0.0822 
2024-02-13
2023-12-31-0.32-0.220.131 
2022-11-04
2022-09-30-0.28-0.38-0.135 
2021-01-29
2020-12-31-0.12-0.22-0.183 
2024-05-14
2024-03-31-0.33-0.220.1133 
View All Earnings Estimates

Biovie Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Biovie Inc Stock. Current markets are strongly bearish. About 75% of major world exchanges and indexes are down. See today's market update for more information.
seekingalpha News
21st of November 2024
BioVie files to sell 7.71M shares of common stock for holders
at seekingalpha.com 
Macroaxis News
7th of November 2024
Acquisition by Berman Richard J of 51830 shares of Biovie subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News: globenewswire.com
28th of October 2024
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nas...
at globenewswire.com 
Yahoo News
23rd of October 2024
Disposition of 1000 shares by Adams Jonathan M of Biovie subject to Rule 16b-3
at finance.yahoo.com 
Macroaxis News: globenewswire.com
21st of October 2024
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placeme...
at globenewswire.com 
news
11th of October 2024
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money S...
at accesswire.com 
Google News at Macroaxis
26th of September 2024
12 Health Care Stocks Moving In Thursdays After-Market Session - Benzinga
at news.google.com 
benzinga news
24th of September 2024
Why BioVie Stock Is Down Over 50 percent Today
at benzinga.com 
Macroaxis News: globenewswire.com
16th of September 2024
BioVie Secures All Scientific Approvals Needed to Receive Additional 12.6 Million of Grant...
at globenewswire.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biovie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biovie's short interest history, or implied volatility extrapolated from Biovie options trading.
When determining whether Biovie Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biovie's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biovie Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biovie Inc Stock:
Check out Biovie Backtesting and Biovie Hype Analysis.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biovie. If investors know Biovie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.08)
Return On Assets
(0.67)
Return On Equity
(2.08)
The market value of Biovie Inc is measured differently than its book value, which is the value of Biovie that is recorded on the company's balance sheet. Investors also form their own opinion of Biovie's value that differs from its market value or its book value, called intrinsic value, which is Biovie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biovie's market value can be influenced by many factors that don't directly affect Biovie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biovie's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biovie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biovie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.